Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Researchers identify better way to screen for lung cancer

Researchers identify better way to screen for lung cancer

The Valley Hospital in Ridgewood, NJ, is pleased to announce that two of its oncologists and a research scientist are helping pave the way to an easier, more accurate, less invasive way to screen for the most common form of lung cancer. Lung cancer is the most common cancer in men worldwide and the number one cancer killer in the United States. [More]
CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports. [More]
New chemical compound reduces pancreatic cancer tumour growth by 80% in mice

New chemical compound reduces pancreatic cancer tumour growth by 80% in mice

Scientists from UCL (University College London) have designed a chemical compound that has reduced the growth of pancreatic cancer tumours by 80 percent in treated mice. [More]
Gene-encoded protein may be effective in early detection of pancreatic cancer

Gene-encoded protein may be effective in early detection of pancreatic cancer

A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center. [More]
Johns Hopkins researchers identify multiple genetic changes that may increase risk of pancreatic cancer

Johns Hopkins researchers identify multiple genetic changes that may increase risk of pancreatic cancer

In a genome-wide association study believed to be the largest of its kind, Johns Hopkins researchers have uncovered four regions in the human genome where changes may increase the risk of pancreatic cancer. [More]
Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. [More]
Canadian and Israeli researchers meet to discuss underlying mechanisms that drive pancreatic cancer

Canadian and Israeli researchers meet to discuss underlying mechanisms that drive pancreatic cancer

Leading Canadian and Israeli scientists gathered at the Hebrew University of Jerusalem's Faculty of Medicine to attend a forum on pancreatic cancer research and help dedicate the Alex U. Soyka Pancreatic Cancer Research Project. [More]
New open access journal to deliver case reports on all aspects of pancreatic cancer

New open access journal to deliver case reports on all aspects of pancreatic cancer

Case Reports in Pancreatic Cancer, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, will deliver authoritative case reports on all aspects of pancreatic cancer diagnosis, management, treatment, and outcomes. [More]
Study: Nut consumption associated with decreased risk of some types of cancer, but not type 2 diabetes

Study: Nut consumption associated with decreased risk of some types of cancer, but not type 2 diabetes

Cancer and type 2 diabetes are two of the most significant public health burdens facing the world today, and currently available data suggests their prevalence is expected to continue to increase. Nut consumption has long been hypothesized to have a role in preventing both of these diseases, but until now evidence has been inconsistent. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform. [More]
El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital in Mountain View, California has enrolled the first patient in a safety study using the RenovoCath, a new catheter that is being introduced for targeted delivery of fluids to selected sites in the peripheral vascular system. The study will help physicians determine appropriate dosing of locally-delivered chemotherapy for patients with pancreatic cancer. [More]
Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments. [More]
NCCN to host policy summit on emerging issues in tissue allocation

NCCN to host policy summit on emerging issues in tissue allocation

Tissue allocation is a growing issue of concern for many researchers due, in part, to expanding research interests in precision medicine. The increased demand by pharmaceutical and biotech companies for patient tissue specimens collected for clinical care and trials presents clinical, ethical, and legal issues. [More]
PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer. [More]
Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. [More]
PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. [More]
ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
Advertisement
Advertisement